← 返回

FLT3L 联合 GM-CSF 诱导的树突状细胞驱动广泛的肿瘤特异性 CD8(+) T 细胞应答并重塑肿瘤微环境以增强抗肿瘤疗效

英文原题:FLT3L combined with GM-CSF induced dendritic cells drive broad tumor-specific CD8(+) T cell responses and remodel the tumor microenvironment to enhance anti-tumor efficacy.

查看英文原题

FLT3L combined with GM-CSF induced dendritic cells drive broad tumor-specific CD8(+) T cell responses and remodel the tumor microenvironment to enhance anti-tumor efficacy.

PubMed 2025/09/04(内容时间) Front Immunol Q1 · IF 7(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

研究概要

FLT3L 联合 GM-CSF 诱导的 DC,通过其独特的亚群组成和功能状态,能够更有效地扩增肿瘤特异性 CD8+T 细胞并重塑肿瘤微环境,从而实现更优的免疫治疗结局。本研究凸显了 FL/GM-DC 作为下一代 DC 平台的潜力,为改善 DC 过继性肿瘤免疫治疗的临床转化铺平了道路。

研究思路结论见上方概要

树突状细胞(DCs)在抗肿瘤免疫中通过捕获、加工并向T细胞呈递肿瘤抗原发挥关键作用,使基于DC的免疫治疗成为癌症治疗的一种有前景的方法。然而,最常用的临床策略仍依赖于使用粒细胞-巨噬细胞集落刺激因子(GM-CSF)和白细胞介素-4(IL-4)在体外诱导DCs(GM/IL4-DCs),这往往导致细胞群体异质性且抗肿瘤功能欠佳。在此,我们将通过FMS样酪氨酸激酶3配体(FLT3L)和GM-CSF共刺激生成的DCs(FL/GM-DCs)与传统的GM/IL4-DCs进行了比较。

为了比较不同方法诱导的DCs的功能差异,我们开展了一项综合研究。将小鼠骨髓细胞在含FLT3L/GM-CSF的培养基中连续培养9天。收集细胞后,我们使用流式细胞术和scRNA-seq分析了FL/GM-DCs的组成、亚群和状态。流式细胞术还用于评估其抗原呈递和刺激T细胞的能力。进行体内实验以检查其在肿瘤模型中的分布、抗肿瘤效果和治疗反应。最后,结合scRNA-seq和scTCR-seq,我们探索了FL/GM-DCs重塑肿瘤微环境的机制。

结果显示,FL/GM-DCs 展现出独特的亚群分布,以常规 cDC 亚群丰富为特征,并表现出增强的交叉抗原呈递能力。值得注意的是,FL/GM-DCs 能够诱导更广泛且更具肿瘤特异性的 CD8 + T 细胞应答,通过促进细胞毒性 T 淋巴细胞(CTLs)的浸润并减少免疫抑制成分,有效重塑肿瘤微环境。相比之下,GM/IL4-DCs 所含 cDC 亚群较少,引发的初始 CD8 + T 细胞应答较弱,抗肿瘤效果相对较差。

展开英文摘要原文

Dendritic cells (DCs) play a crucial role in anti-tumor immunity by capturing, processing, and presenting tumor antigens to T cells, making DC-based immunotherapy a promising approach for cancer treatment. However, the most commonly used clinical strategy still relies on inducing DCs in vitro using granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin-4 (IL - 4) (GM/IL4-DCs), which often results in a heterogeneous cell population with suboptimal anti-tumor function. Here, we compared DCs generated by co-stimulating with FMS-like tyrosine kinase 3 ligand (FLT3L) and GM-CSF (FL/GM-DCs) with the conventional GM/IL4-DCs. METHOD: To compare the functional differences of DCs induced by different methods, we conducted a comprehensive study. Mouse bone marrow cells were continuously cultured for 9 days in a FLT3L/GM-CSF-containing medium. After cell collection, we analyzed the composition, subpopulations, and status of FL/GM-DCs using flow cytometry and scRNA-seq. Flow cytometry was also used to assess their antigen presentation and ability to stimulate T cells. In vivo experiments were performed to examine their distribution, anti-tumor effects, and therapeutic responses in tumor models. Finally, combining scRNA-seq and scTCR-seq, we explored the mechanisms by which FL/GM-DCs reshape the tumor microenvironment.

The results showed that FL/GM-DCs exhibited a unique subpopulation distribution, characterized by an abundance of conventional cDC subpopulations, and demonstrated enhanced cross-antigen presentation capabilities. Notably, FL/GM-DCs were able to induce a broader and more tumor-specific CD8 + T cell response, effectively reshaping the tumor microenvironment by promoting the infiltration of cytotoxic T lymphocytes (CTLs) and reducing immunosuppressive components. In contrast, GM/IL4-DCs contained fewer cDC subpopulations, eliciting a weaker initial CD8 + T cell response and yielding relatively inferior anti-tumor effects.

In summary, FLT3L combined with GM-CSF induced DCs, through their unique subpopulation composition and functional state, can more effectively expand tumor-specific CD8 + T cells and reshape the tumor microenvironment, thereby achieving superior immunotherapy outcomes. This study highlights the potential of FL/GM-DCs as a next-generation DC platform, paving the way for improved clinical translation of DC-based adoptive cancer immunotherapies.

论文信息

作者
Zheng Q、Zhang J、Sui H、Sun Y、Lv N、Liu L、Qu M、Tan J
第一作者单位
Department of Endoscopy Center, China-Japan Union Hospital of Jilin University, Changchun, China.China
通讯作者单位
Department of Radiology, China-Japan Union Hospital of Jilin University, Changchun, China.China
期刊
Frontiers in immunology2025
原文标识
PubMed 40977690 · DOI 10.3389/fimmu.2025.1649891